Impact News +++ Futures Drop As Powell Dovish Pivot Euphoria Fades (ZeroHedge) +++ INTEL Aktie -3,00%

ARGENX Aktie

>ARGENX Aktienkurs

580.2 EUR +3.0% (Tradegate)

Ask: 596 EUR / 16 Stück

Bid: 595.6 EUR / 16 Stück

Tagesumsatz: 128 Stück

Realtime Kurs von 8 bis 22 Uhr!

ARGENX Aktie über LYNX handeln

Intraday

1 Jahr

>ARGENX Performance

1 Woche: +2,3%

1 Monat: +16,4%

3 Monate: +9,9%

6 Monate: -8,6%

1 Jahr: +21,4%

laufendes Jahr: -5,0%

>ARGENX Aktie

Name:

ARGENX SE EO -,10

Land:

Niederlande

Sektor:

Gesundheit

ISIN/ Wkn:

NL0010832176 / A11602

Symbol/ Ticker:

1AE (Frankfurt)

Kürzel:

FRA:1AE, ETR:1AE, 1AE:GR

Index:

Webseite:

https://www.argenx.com/

Profil:

Argenx SE is a biotechnology company specializing ..
>Volltext..

Marktkapitalisierung:

34287.91 Mio. EUR

Unternehmenswert:

31009.51 Mio. EUR

Umsatz:

2818.69 Mio. EUR

EBITDA:

382.23 Mio. EUR

Nettogewinn:

1185.8 Mio. EUR

Gewinn je Aktie:

19.69 EUR

Schulden:

36.96 Mio. EUR

Liquide Mittel:

1786.65 Mio. EUR

Operativer Cashflow:

497.5 Mio. EUR

Bargeldquote:

3.77

Umsatzwachstum:

87.66%

Gewinnwachstum:

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

ARGENX

Letzte Datenerhebung:

25.08.25

>ARGENX Kennzahlen

Aktien/ Unternehmen:

Aktien: 61.2 Mio. St.

Frei handelbar: 99.9%

Leerverk. Aktien: -

Rückkaufquote: -0.93%

Mitarbeiter: 1599

Umsatz/Mitarb.: 1.12 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 23.67%

Bewertung:

KGV: 31.24

KGV lG: 43.01

KUV: 13.47

KBV: 6.66

PEG-Ratio: -

EV/EBITDA: 81.13

Rentabilität:

Bruttomarge: 88.95%

Gewinnmarge: 42.07%

Operative Marge: 12.83%

Managementeffizenz:

Gesamtkaprendite: 22.28%

Eigenkaprendite: 25.72%

>ARGENX Peer Group

Es sind 19 Aktien bekannt.

>ARGENX Chart & Kurs - Tradegate

>ARGENX News

25.08.25 - 07:48	Argenx′s VYVGART Achieves Primary Endpoint In Pivotal Study For AChR-Ab Seronegative GMG (AFX)
	AMSTERDAM (dpa-AFX) - argenx SE (ARGX) reported that the pivotal ADAPT SERON study of VYVGART (IV: efgartigimod alfa-fcab) successfully met its primary endpoint. The study demonstrated a statistic......

25.08.25 - 07:03	argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG (GlobeNewswire EN)
	August 25, 2025, 7:00 AM CET...

19.08.25 - 07:03	argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025 (GlobeNewswire EN)
	August 19, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced it will host a webinar, titled “R&D Spotlight \| Pioneering MuSK Biology with ARGX-119” on Tuesday, September 16, 2025, at 2:00pm ET....

12.08.25 - 12:48	argenx and Tennis Legend Monica Seles Team Up to Raise Awareness of Myasthenia Gravis (GlobeNewswire EN)
	Seles speaks out about her diagnosis with MG, a chronic autoimmune disease that causes muscle weakness, which can be severe and significantly impact daily life...

31.07.25 - 11:09	Argenx stock soars on strong second-quarter global product sales (Investing.com)
	Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

31.07.25 - 09:00	argenx SE GAAP EPS of $6.32 beats by $0.83, revenue of $1.74B beats by $50M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

31.07.25 - 07:03	argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update (GlobeNewswire EN)
	$949 million in second quarter global product net sales...

30.07.25 - 18:09	argenx SE 1H 2025 Earnings Preview (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

29.07.25 - 03:18	$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today (Benzinga)
	read more...

24.07.25 - 07:03

argenx to Report Half Year 2025 Financial Results and Second Quarter Business Update on July 31, 2025 (GlobeNewswire EN)

July 24, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, July 31, 2025 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its half year 2025 financial results and provide a second quarter business update....

12.07.25 - 16:21	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX (PR Newswire)
	NEW YORK, July 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE ("argenx" or the "Company") (NASDAQ: ARGX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation......

07.07.25 - 22:01	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX (PR Newswire)
	NEW YORK, July 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE ("argenx" or the "Company") (NASDAQ: ARGX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns......

02.07.25 - 22:30	Heres How Much You Would Have Made Owning argenx Stock In The Last 5 Years (Benzinga)
	read more...

30.06.25 - 18:12	argenx down 7% as FDA identifies possible safety signal with Vyvgart Hytrulo (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

30.06.25 - 07:03	argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes (GlobeNewswire EN)
	Um den gesamten Artikel unter globenewswire.com zu lesen, klicken Sie bitte auf die Überschrift...

20.06.25 - 20:21	argenx gets EU nod for Vyvgart subcutaneous injection (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

20.06.25 - 19:18	Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (PR Newswire)
	SC injection of VYVGART® is available as a vial or prefilled syringe and can be administered by a patient, caregiver, or healthcare professional SAN DIEGO, June 20, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx received European......

20.06.25 - 19:03	argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (GlobeNewswire EN)
	June 20, 2025, 7:00 PM CET...

11.06.25 - 00:03	argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren′s Disease (GlobeNewswire EN)
	June 11, 2025, 12:01 AM CET...

03.06.25 - 07:03

argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire EN)

June 3, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Karl Gubitz, Chief Financial Officer, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025 at 8:40 AM ET in Miami, FL....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Im strengen Sinne des Wortes hat es nie eine wirkliche Demokratie gegeben und wird es niemals geben. - Jean-Jacques Rousseau

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram